We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · May 11, 2022

Blood-Based Tumor Mutational Burden as a Biomarker for Atezolizumab in NSCLC

Nature Medicine

 

Additional Info

Nature Medicine
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
Nat. Med. 2022 Apr 14;[EPub Ahead of Print], ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan, S Hu, YK Chae, TA Leal, JE Dowell, ML Tsai, CSR Dakhil, P Stella, Y Jin, DS Shames, E Schleifman, DA Fabrizio, S Phan, MA Socinski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading